The earnings call highlighted strong international sales growth, significant progress in pharmacy channel expansion, and product development milestones. However, it also pointed out challenges in the U.S. market with moderated sales growth and increased competition. Despite these challenges, the company remains optimistic about its long-term goals.

Company Guidance -

Q3 2025

During Tandem Diabetes Care's Second Quarter 2025 Earnings Call, the company provided optimistic guidance and highlighted several key metrics. They achieved record second quarter sales of $241 million, a 15% increase year-to-date, with $170 million from the U.S. showing a 9% growth. The company expects to reach $1 billion in worldwide sales by year-end, with $700 million from the U.S. and $300 million internationally. Gross margins are projected to be between 53% and 54%, with a target of 60% by the end of 2026. Tandem plans to expand its pharmacy channel, which currently covers 30% of U.S. lives, to improve margins and patient access. They also aim to enhance their presence in the type 2 diabetes market and have received favorable responses to their Tandem Mobi and t:slim X2 platforms. International sales are expected to be stronger than anticipated, with the company preparing for direct operations in 2026.

Record Second Quarter Sales

Achieved record second quarter sales both in the U.S. and internationally with $241 million, marking the highest second quarter sales in the company's history.

Strong International Performance

International sales grew to $70 million, with a rise in pump renewals and favorable currency dynamics. The expected headwind from going direct was reduced from $15-20 million to approximately $10 million.

Pharmacy Channel Expansion

Progress in the pharmacy channel with 30% of U.S. lives covered and plans to start selling t:slim supplies in Q4, potentially lowering out-of-pocket costs for patients.

Product Development Milestones

Achieved compatibility with Abbott's FreeStyle Libre 3 Plus sensor and began early access for integration. Also, received CE Mark for Tandem Mobi and submitted a Steadiset 510(k) for extended wear time.

Gross Margin Improvement

Gross margin improved to 52% in the second quarter, driven by pricing and operational efficiencies, with a target of reaching 60% by the end of 2026.

Tandem Diabetes Care (TNDM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TNDM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.32 / -	-0.35	―	―	―
Aug 06, 2025	2025 (Q2)	-0.40 / -0.48	-0.47	-2.55% (-0.01)
Apr 30, 2025	2025 (Q1)	-0.60 / -0.67	-0.65	-2.92% (-0.02)
Feb 26, 2025	2024 (Q4)	-0.20 / 0.01	-0.46	102.17% (+0.47)
Nov 06, 2024	2024 (Q3)	-0.40 / -0.35	-0.51	31.37% (+0.16)
Aug 01, 2024	2024 (Q2)	-0.54 / -0.47	-0.55	14.55% (+0.08)
May 02, 2024	2024 (Q1)	-0.76 / -0.65	-1.92	66.15% (+1.27)
Feb 21, 2024	2023 (Q4)	-0.26 / -0.46	-0.25	-84.00% (-0.21)
Nov 01, 2023	2023 (Q3)	-0.48 / -0.51	-0.76	32.89% (+0.25)
Aug 03, 2023	2023 (Q2)	-0.50 / -0.55	-0.24	-129.17% (-0.31)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TNDM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$14.39	$11.52	-19.94%
Apr 30, 2025	$16.85	$19.98	+18.58%
Feb 26, 2025	$33.59	$21.75	-35.25%
Nov 06, 2024	$34.24	$33.32	-2.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.